Esophageal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Esophageal Cancer pipeline constitutes 80+ key companies continuously working towards developing 100+ Esophageal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Esophageal Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Cancer Market.

The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Esophageal Cancer Pipeline Report: https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Esophageal Cancer treatment therapies with a considerable amount of success over the years.
• Esophageal Cancer companies working in the treatment market are Coherus Oncology, Inc., Iksuda Therapeutics Ltd, Akeso Biopharma, Sumit Therapeuics, Shanghai Henlius Biotech, Roche, Beijing Konruns Pharmaceutical Co., Ltd, Astellas Pharma, BeOne, and others, are developing therapies for the Esophageal Cancer treatment
• Emerging Esophageal Cancer therapies in the different phases of clinical trials are- CHS-114, IKS014, Ivonescimab, HLX43, Atezolizumab, KC1036, Zolbetuximab, TEVIMBRA, and others are expected to have a significant impact on the Esophageal Cancer market in the coming years.
• In October 2025, Astellas Pharma Canada Inc. announced that VYLOY(R) (zolbetuximab) was funded by the Ontario Drug Benefit Program under the New Drug Funding Program and in Quebec through the Liste des médicaments - Établissements de la RAMQ. VYLOY was funded as a first-line treatment for adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours were claudin (CLDN) 18.2 positive as determined by a validated test in both provinces.
• In July 2025, Iksuda Therapeutics announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IKS014, a human epidermal growth factor receptor 2 (HER2) ADC targeting patients with advanced HER2+ solid tumours, enabling the expansion of ongoing clinical trials.

Esophageal Cancer Overview
Esophageal cancer is a type of cancer that forms in the tissues of the esophagus, the muscular tube that carries food and liquids from the mouth to the stomach. The two main types of esophageal cancer are squamous cell carcinoma, which occurs in the cells lining the esophagus, and adenocarcinoma, which often develops in the lower part of the esophagus near the stomach. Risk factors include smoking, heavy alcohol consumption, obesity, and gastroesophageal reflux disease (GERD). Symptoms may include difficulty swallowing, chest pain, unexplained weight loss, and persistent heartburn. Early detection is crucial, and treatment options include surgery, radiation, chemotherapy, and targeted therapy, depending on the cancer's stage.

Get a Free Sample PDF Report to know more about Esophageal Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Esophageal Cancer Drugs Under Different Phases of Clinical Development Include:
• CHS-114: Coherus Oncology, Inc.
• IKS014: Iksuda Therapeutics Ltd
• Ivonescimab: Akeso Biopharma/Sumit Therapeuics
• HLX43: Shanghai Henlius Biotech
• Atezolizumab: Roche
• KC1036: Beijing Konruns Pharmaceutical Co., Ltd
• Zolbetuximab: Astellas Pharma
• TEVIMBRA: BeOne

Esophageal Cancer Route of Administration
Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Esophageal Cancer Molecule Type
Esophageal Cancer Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Esophageal Cancer Pipeline Therapeutics Assessment
• Esophageal Cancer Assessment by Product Type
• Esophageal Cancer By Stage and Product Type
• Esophageal Cancer Assessment by Route of Administration
• Esophageal Cancer By Stage and Route of Administration
• Esophageal Cancer Assessment by Molecule Type
• Esophageal Cancer by Stage and Molecule Type

DelveInsight's Esophageal Cancer Report covers around 100+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Esophageal Cancer product details are provided in the report. Download the Esophageal Cancer pipeline report to learn more about the emerging Esophageal Cancer therapies
https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Esophageal Cancer Therapeutics Market include:
Key companies developing therapies for Esophageal Cancer are - Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others.

Esophageal Cancer Pipeline Analysis:
The Esophageal Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
• Esophageal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Esophageal Cancer drugs and therapies
https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Esophageal Cancer Pipeline Market Drivers
• Increase in the number of cases of Esophageal Cancer, increasing research and development and launches of novel products by key players are some of the important factors that are fueling the Esophageal Cancer Market.

Esophageal Cancer Pipeline Market Barriers
• However, high cost of therapy for the treatment of esophageal cancer, side effects associated with the current treatment options and other factors are creating obstacles in the Esophageal Cancer Market growth.

Scope of Esophageal Cancer Pipeline Drug Insight
• Coverage: Global
• Key Esophageal Cancer Companies: Coherus Oncology, Inc., Iksuda Therapeutics Ltd, Akeso Biopharma, Sumit Therapeuics, Shanghai Henlius Biotech, Roche, Beijing Konruns Pharmaceutical Co., Ltd, Astellas Pharma, BeOne, and others
• Key Esophageal Cancer Therapies: CHS-114, IKS014, Ivonescimab, HLX43, Atezolizumab, KC1036, Zolbetuximab, TEVIMBRA, and others
• Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
• Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.